IO Biotech, Inc. 8-K

What Happened

• IO Biotech, Inc. filed an 8-K reporting that its Board approved a restructuring and workforce reduction plan on January 21, 2026, as the company explores a range of strategic alternatives. The company expects one-time charges and cash expenditures of approximately $2.4 million to $2.6 million, primarily for employee wages, severance, healthcare continuation, and accrued vacation, mainly to be incurred in the first quarter of 2026.
• The company also notified Chief Medical Officer and named executive officer Qasim Ahmad, M.D., on January 28, 2026, that his employment will end effective February 15, 2026. IO Biotech announced it has engaged an exclusive financial advisor to assist in its exploration of strategic alternatives (press release filed as Exhibit 99.1).

Key Details

• Board approved restructuring plan date: January 21, 2026.
• Estimated one-time charges/cash expenditures: $2.4M–$2.6M, expected primarily in Q1 2026.
• CMO departure: Qasim Ahmad, M.D.; notified January 28, 2026; termination effective February 15, 2026.
• Company engaged an exclusive financial advisor to support exploration of strategic alternatives; a press release was filed on January 30, 2026.

Why It Matters

• The restructuring is intended to reduce operating expenses while IO Biotech evaluates strategic options; investors should note a near-term cash outflow of about $2.4–$2.6M for severance and related costs.
• Management change (departure of the CMO) may affect clinical or regulatory activities and leadership continuity; investors may want to watch for announcements about a replacement or interim coverage.
• Retaining an exclusive financial advisor signals the company is actively pursuing strategic alternatives (e.g., partnerships, asset sales, or other transactions); no transaction was announced in this filing.